New and emerging treatments for osteoarthritis management: Will the dream come true with personalized medicine?

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2059-2077

  Roubille, Camille ^a   Pelletier, Jean Pierre ^a,b   Martel Pelletier, Johanne ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Disease modifying osteoarthritis drug; Gene therapy; Knee osteoarthritis; MRI; Stem cells; Strontium ranelate; Subchondral bone

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; CALCITONIN; CANAKINUMAB; CATHEPSIN K INHIBITOR; CINDUNISTAT; COMPLEMENTARY DNA; CORTICOSTEROID; CYTOKINE; DENOSUMAB; FIBROBLAST GROWTH FACTOR 18; GEVOKIZUMAB; HYALURONIC ACID; INFLIXIMAB; METHOTREXATE; MICRORNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; PARACETAMOL; PARATHYROID HORMONE[1-34]; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VITAMIN D;

BONE REMODELING; CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CATABOLISM; FIBROBLAST; FOLLOW UP; GENE THERAPY; GRIP STRENGTH; HAND OSTEOARTHRITIS; HUMAN; IN VIVO GENE TRANSFER; KNEE INJURY AND OSTEOARTHRITIS OUTCOME SCORE; KNEE OSTEOARTHRITIS; KNEE PAIN; MACROPHAGE; MENISCECTOMY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MORNING STIFFNESS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PERSONALIZED MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; VISUAL ANALOG SCALE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE REMODELING; CARTILAGE; GENETIC THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; OSTEOARTHRITIS; RNA INTERFERENCE;

EID: 84884586094     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.825606     Document Type: Review

References (125)

1. Goldring MB. Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis. Ther Adv Musculoskelet Dis 2012;4:269-85
2. Jelic M, Pecina M, Haspl M, et al. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 2001;19:101-13
3. Gavenis K, Heussen N, Schmidt-Rohlfing B. Effects of low concentration BMP-7 on human osteoarthritic chondrocytes: comparison of different applications. J Biomater Appl 2012;26:845-59
4. Hunter DJ, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010;11:232
5. Available from: www.clinicaltrials.gov
6. Moore EE, Bendele AM, Thompson DL, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005;13:623-31
7. McPherson R, Flechsenhar K, Hellot S, et al. A randomized, double-blind, placebo-controlled, multicenter study of rhFGF18 administered intraarticularly using single or multiple ascending doses in patients with primary knee osteoarthritis (OA), not expected to require knee surgery within 1 year. Osteoarthritis Cartilage 2011;19(Suppl 1):S35-S6
8. Pietrzak WS, An YH, Kang QK, et al. Platelet-rich and platelet-poor plasma: development of an animal model to evaluate hemostatic efficacy. J Craniofac Surg 2007;18:559-67
9. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:4-15
10. Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy-future or trend? Arthritis Res Ther 2012;14:219
11. Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013;41:356-64
12. Taylor DW, Petrera M, Hendry M, et al. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med 2011;21:344-52
13. Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy 2011;27:1490-501
14. Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010;18:472-9
15. Sampson S, Reed M, Silvers H, et al. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 2010;89:961-9
16. Sanchez M, Anitua E, Azofra J, et al. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol 2008;26:910-13
17. Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord 2012;13:229
18. Spakova T, Rosocha J, Lacko M, et al. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 2012;91:411-17
19. Sanchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGFEndoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy 2012;28:1070-8
20. Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone 2012;51:297-311
21. Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998;41:1275-86
22. Hellio le Graverand MP, Clemmer RS, Redifer P, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013;72:187-95
23. Muhammad H, Schminke B, Miosge N. Current concepts in stem cell therapy for articular cartilage repair. Expert Opin Biol Ther 2013;13:541-8
24. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7
25. Gupta PK, Das AK, Chullikana A, et al. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res Ther 2012;3:25
26. Johnson K, Zhu S, Tremblay MS, et al. A stem cell-based approach to cartilage repair. Science 2012;336:717-21
27. Murphy JM, Fink DJ, Hunziker EB, et al. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-74
28. Grigolo B, Lisignoli G, Desando G, et al. Osteoarthritis treated with mesenchymal stem cells on hyaluronan-based scaffold in rabbit. Tissue Eng Part C Methods 2009;15:647-58
29. Alfaqeh H, Norhamdan MY, Chua KH, et al. Cell based therapy for osteoarthritis in a sheep model: gross and histological assessment. Med J Malaysia 2008;63(Suppl A):37-8
30. ter Huurne M, Schelbergen R, Blattes R, et al. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum 2012;64:3604-13
31. Toupet K, Maumus M, Peyrafitte JA, et al. Long-term detection of human adipose derived mesenchymal stem cells after intra-articular injection in SCID mice. Arthritis Rheum 2013;65:1786-94
32. Diekman BO, Guilak F. Stem cell-based therapies for osteoarthritis: challenges and opportunities. Curr Opin Rheumatol 2013;25:119-26
33. Kuroda R, Ishida K, Matsumoto T, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage 2007;15:226-31
34. Wakitani S, Nawata M, Tensho K, et al. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med 2007;1:74-9
35. Davatchi F, Abdollahi BS, Mohyeddin M, et al. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011;14:211-15
36. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med 2012;15:422-8
37. Koh YG, Jo SB, Kwon OR, et al. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy 2013;29:748-55
38. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee 2012;19:902-7
39. Estes BT, Diekman BO, Gimble JM, et al. Isolation of adipose-derived stem cells and their induction to a chondrogenic phenotype. Nat Protoc 2010;5:1294-311
40. Filardo G, Madry H, Jelic M, et al. Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Knee Surg Sports Traumatol Arthrosc 2013;21:1717-29
41. Kim HJ, Im GI. Chondrogenic differentiation of adipose tissue-derived mesenchymal stem cells: greater doses of growth factor are necessary. J Orthop Res 2009;27:612-19
42. Afizah H, Yang Z, Hui JH, et al. A comparison between the chondrogenic potential of human bone marrow stem cells (BMSCs) and adipose-derived stem cells (ADSCs) taken from the same donors. Tissue Eng 2007;13:659-66
43. Jorgensen C, Noel D. Mesenchymal stem cells in osteoarticular diseases. Regen Med 2011;6:44-51
44. Roldan M, Macias-Gonzalez M, Garcia R, et al. Obesity short-circuits stemness gene network in human adipose multipotent stem cells. FASEB J 2011;25:4111-26
45. Suri S, Walsh DA. Osteochondral alterations in osteoarthritis. Bone 2012;51:204-11
46. Kwan Tat S, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70
47. Lajeunesse D, Pelletier JP, Martel-Pelletier J. Osteoporosis and osteoarthritis: bone is the common battle ground. Medicographia 2010;32:391-8
48. Pelletier JP, Troncy E, Bertaim T, et al. Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. J Rheumatol 2011;38:118-28
49. Moreau M, Rialland P, Pelletier JP, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011;13:R98
50. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-25
51. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33
52. Bingham CO III, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507
53. Tat SK, Pelletier JP, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone 2011;49:559-67
54. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16:299-308
55. Pelletier JP, Kapoor M, Fahmi H, et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1beta in the synovium. Ann Rheum Dis 2013;72:250-7
56. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9
57. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013;72:179-86
58. Martel-Pelletier J, Roubille C, Raynauld JP, et al. Disease modifying effect of strontium ranelate in a phase III knee osteoarthritis study (SEKOIA) using quantitative MRI: reduction in bone marrow lesion size associated with cartilage protective effect. Osteoporos Int 2013;24:S51 MRI, with a beneficial effect on both cartilage and subchondral bone.
59. Roux C, Richette P. Impact of treatments for osteoporosis on osteoarthritis progression. Osteoporos Int 2012;23(Suppl 8):S881-3
60. Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012;71:1322-8
61. Tat SK, Pelletier JP, Velasco CR, et al. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 2009;58:29-40
62. Kwan Tat S, Pelletier JP, Lajeunesse D, et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008;26:295-304
63. Kwan Tat S, Amiable N, Pelletier JP, et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009;48:1482-90
64. Pilichou A, Papassotiriou I, Michalakakou K, et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 2008;41:746-9
65. Kadri A, Ea HK, Bazille C, et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008;58:2379-86
66. Josse R, Khan A, Ngui D, et al. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin 2013;29:205-16
67. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309
68. Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012;50:1250-9
69. Sampson ER, Hilton MJ, Tian Y, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med 2011;3:101ra93
70. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54:3205-11
71. Esenyel M, Icagasioglu A, Esenyel CZ. Effects of calcitonin on knee osteoarthritis and quality of life. Rheumatol Int 2013;33:423-7
72. Karsdal MA, Alexandersen P, John MR, et al. Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year Phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2011;19:S35
73. Reginster JY, Pelousse F, Bruyere O. Safety concerns with the long-term management of osteoporosis. Expert Opin Drug Saf 2013;12:507-22
74. McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA 2013;309:155-62
75. Cao Y, Jones G, Cicuttini F, et al. Vitamin D supplementation in the management of knee osteoarthritis: study protocol for a randomized controlled trial. Trials 2012;13:131
76. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33-42
77. Wu X, Kondragunta V, Kornman KS, et al. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthritis Cartilage 2013;21:930-8
78. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996;39:1535-44
79. Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23
80. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009;61:344-52
81. Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 2009;68:1078-9
82. Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011;13:R125
83. Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthritis Res Ther 2011;13:124
84. Martel-Pelletier J, Pelletier JP. Osteoarthritis: a single injection of anakinra for treating knee OA? Nat Rev Rheumatol 2009;5:363-4
85. Yang KG, Raijmakers NJ, van Arkel ER, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008;16:498-505
86. Baltzer AW, Moser C, Jansen SA, et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009;17:152-60
87. Fioravanti A, Fabbroni M, Cerase A, et al. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009;29:961-5
88. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323-7
89. Verbruggen G, Wittoek R, Vander Cruyssen B, et al. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 2012;71:891-8
90. Chevalier X, Ravaud P, Maheu E, et al. A randomized, multicentre, double blind, placebo-controlled trial of antiTNFalpha (adalimumab) in refractory hand osteoarthritis: the Dora study. Arthritis Rheum 2012;64:S1042
91. Maksymowych WP, Russell AS, Chiu P, et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther 2012;14:R206
92. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013;9:400-10
93. Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006;8:R187
94. Tsuneyoshi Y, Tanaka M, Nagai T, et al. Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. Scand J Rheumatol 2012;41:132-40
95. Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis 2011;70:1282-4
96. de Boer TN, van Spil WE, Huisman AM, et al. Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage 2012;20:846-53
97. Kyrkanides S, Tallents RH, Miller JN, et al. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. J Neuroinflammation 2011;8:112
98. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013;21:16-21
99. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy and its tortuous path into the clinic. Transl Res 2013;161:205-16
100. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-19
101. Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999;154:1159-69
102. Bakker AC, Joosten LA, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997;40:893-900
103. Otani K, Nita I, Macaulay W, et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996;156:3558-62
104. Evans CH, Robbins PD, Ghivizzani SC, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996;7:1261-80
105. Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 2005;102:8698-703
106. Ha CW, Noh MJ, Choi KB, et al. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy 2012;14:247-56
107. Gouze E, Gouze JN, Palmer GD, et al. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther 2007;15:1114-20
108. Kay JD, Gouze E, Oligino TJ, et al. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med 2009;11:605-14
109. Watson RS, Broome TA, Levings PP, et al. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther 2013;20(6):670-7
110. Apparailly F, Jorgensen C. siRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol 2013;9:56-62
111. Santangelo KS, Bertone AL. Effective reduction of the interleukin-1beta transcript in osteoarthritis-prone guinea pig chondrocytes via short hairpin RNA mediated RNA interference influences gene expression of mediators implicated in disease pathogenesis. Osteoarthritis Cartilage 2011;19:1449-57
112. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008;16:174-84
113. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
114. Xu J, Kang Y, Liao WM, et al. MiR-194 regulates chondrogenic differentiation of human adipose-derived stem cells by targeting Sox5. PLoS One 2012;7:e31861
115. Tardif G, Hum D, Pelletier JP, et al. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord 2009;10:148
116. Miyaki S, Sato T, Inoue A, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev 2010;24:1173-85
117. Yamasaki K, Nakasa T, Miyaki S, et al. Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis Rheum 2009;60:1035-41
118. Miyaki S, Asahara H. Macro view of microRNA function in osteoarthritis. Nat Rev Rheumatol 2012;8:543-52
119. Pers YM, Jorgensen C. MicroRNA in 2012: Biotherapeutic potential of microRNAs in rheumatic diseases. Nat Rev Rheumatol 2013;9:76-8
120. Dodin P, Abram F, Pelletier JP, et al. A fully automated system for quantification of knee bone marrow lesions using MRI and the Osteoarthritis Initiative cohort. J Biomed Graph Comput 2013;3:51-65
121. Dodin P, Martel-Pelletier J, Pelletier JP, et al. A fully automated human knee 3D MRI bone segmentation using the ray casting technique. Med Biol Eng Comput 2011;49:1413-24
122. Dodin P, Pelletier JP, Martel-Pelletier J, et al. Automatic human knee cartilage segmentation from 3D magnetic resonance images. IEEE Trans Biomed Eng 2010;57:2699-711
123. Li W, Abram F, Pelletier JP, et al. Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging. Arthritis Res Ther 2010;12:R173
124. Peeters CM, Leijs MJ, Reijman M, et al. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthritis Cartilage 2013;doi:10.1016/j.joca.2013.06.025
125. Available from: http://www.ema.europa. eu/ema/index.jsp?curl=pages/news- and-events/news/2013/04/news-detail-001774. jsp&mid=WC0b01ac058004d5c1